Proton pump inhibitors are widely used in primary care, without a valid clinical indication. Their inappropriate prolonged use is associated with the risks of adverse effects and healthcare costs. Despite international guidelines on deprescribing, there is limited evidence on structured, collaborative interventions in low-resource settings like Pakistan Proton pump inhibitors adverse effects collaborative interventions , low-resource settings
Conditions
Interventions
Receives a structured deprescribing intervention through collaboration between general practitioner and pharmacist.,Receives usual care from their GP without structured deprescribing intervention
Experimental Other,No Intervention No treatment
Collaborative Deprescribing Intervention Group,Control arm
Sponsors
Capital University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving PPIs for at least three months before enrolment. 2. Participant should show Willingness to participate in the study and provide informed consent 3. Access to primary healthcare settings involved in the study
Exclusion criteria
Exclusion criteria: 1. Confirmed diagnosis requiring long term PPI use 2. Pregnant or breastfeeding women were excluded from the study 3. History of severe gastrointestinal bleeding, peptic ulcer perforation, or malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in prescribed PPI dose over a 6-month follow-up. Baseline, 2 months and 4 Month Mann-Whitney U test (or Wilcoxon rank-sum test) | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of possible side effects caused by chronic and long-term PPI use. Baseline, 2 months and 4 Month Mann-Whitney U test (or Wilcoxon rank-sum test | — |
Countries
Pakistan
Contacts
Public ContactFarman Khan
Faculty of Pharmacy Capital University of Science and Technology
Outcome results
None listed